Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sitagliptin

FDA-approved product (tablet, oral), marketed as Zituvio, Brynovin, Januvia and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sitagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Hyperlipidemia
  • Myocardial infarction
  • Stroke
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sitagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sitagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

    NCT00666458 · start 2008-04

    Registered record
    Registry ID
    NCT00666458
    Conditions
    Type 2 Diabetes
    Interventions
    saxagliptin; sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-04
    Completion
    2009-03
    Enrolment
    822

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    Interventionsaxagliptin; sitagliptin
    PhasePhase 3
    Registry statusCompleted

  • Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)

    NCT00545584 · start 2007-04-01

    Registered record
    Registry ID
    NCT00545584
    Conditions
    Diabetes Mellitus, Non-Insulin-Dependent
    Interventions
    sitagliptin phosphate; Comparator: Diet; Comparator: Physical Activity
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-04-01
    Completion
    2009-11-19
    Enrolment
    1,512

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Non-Insulin-Dependent
    Interventionsitagliptin phosphate; Comparator: Diet; Comparator: Physical Activity
    PhasePhase 3
    Registry statusCompleted

  • Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

    NCT00363948 · start 2006-08

    Registered record
    Registry ID
    NCT00363948
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Placebo; Sitagliptin phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-08
    Completion
    Not recorded
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionPlacebo; Sitagliptin phosphate
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

    NCT00975052 · start 2006-01

    Registered record
    Registry ID
    NCT00975052
    Conditions
    Type 2 Diabetes
    Interventions
    sitagliptin phosphate; Comparator: metformin; Comparator: sitagliptin and metformin; Comparator: placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-01
    Completion
    2006-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    Interventionsitagliptin phosphate; Comparator: metformin; Comparator: sitagliptin and metformin; Comparator: placebo
    PhasePhase 1
    Registry statusCompleted

  • A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

    NCT01077323 · start 2004-09

    Registered record
    Registry ID
    NCT01077323
    Conditions
    Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies); Healthy Subjects (Treated With no Diabetes Therapies)
    Interventions
    exenatide; Other antidiabetic therapies; No diabetes therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-09
    Completion
    2008-03
    Enrolment
    363,766

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies); Healthy Subjects (Treated With no Diabetes Therapies)
    Interventionexenatide; Other antidiabetic therapies; No diabetes therapy
    PhaseNot recorded
    Registry statusCompleted